How ARGEA Works

Why tumours depend on it

Arginine is made in the urea cycle, a chain of enzymes that every healthy cell carries. Two of these enzymes, ASS1 and OTC, are the bottleneck. Switch them off and the cell can no longer produce arginine; it has to import it from the blood.

Many cancers do exactly that. They silence ASS1 because it competes with the fast growth they favour: without ASS1, the raw material aspartate is diverted into building DNA instead of arginine. The tumour grows faster, but at a price. It becomes dependent on an external supply of arginine, a state called arginine auxotrophy.

ASS1 loss has been documented in roughly half or more of mesotheliomas, hepatocellular carcinomas, melanomas and sarcomas, and in substantial shares of pancreatic, prostate, bladder, small-cell lung and some breast cancers, as well as in some leukaemias. OTC loss adds further tumour types. Which tumours are affected can be measured in a biopsy with a routine stain.

What this means for youIf your tumour has lost ASS1 or OTC, it has a weakness your healthy cells do not share. Arginine deprivation targets that weakness and nothing else.

What NGA-8000 does in the blood

NGA-8000 is a recombinant mammalian arginase. Given weekly, it circulates in the blood and converts arginine into ornithine and urea, both harmless, both excreted. Within hours of the first dose, arginine in the blood falls below the detection limit and stays there.

Earlier enzymes for the same purpose had two problems. ADI-PEG 20, a bacterial enzyme, is recognised as foreign; most patients form antibodies after about eight weeks and the drug stops working. Pegzilarginase, a human enzyme, is well tolerated but short-lived. NGA-8000 is built to fix both: a mammalian protein with low immunogenicity, fused to an albumin-binding domain that keeps it in circulation for days rather than hours and shields it from antibodies and from being filtered out by the kidneys.

ReactionArginine → ornithine + urea. Ornithine is a normal metabolite; urea is excreted in urine.

Dose intervalOnce a week. The long half-life keeps arginine suppressed between doses.

Target levelBlood arginine below 10 µmol/L (normal range about 40 to 120 µmol/L). Measured at the start and then regularly, because a rising level is the first sign of antibodies or of a missed dose.

Tumour rangeCells lacking ASS1 or OTC. ADI-PEG 20 acts only on ASS1-negative cells, so NGA-8000 covers more tumour types.

What happens inside a starved cancer cell

A cancer cell without arginine does not simply stop. It runs a survival programme that evolved for short famines. Stretched over months, that programme destroys it.

Growth switch offArginine is sensed by mTORC1, the master switch for growth. Without it, mTORC1 shuts down, protein synthesis halts and the cell stops dividing. Energy stress activates AMPK, a second switch, which turns the cell to self-maintenance.

AutophagyThe cell begins to digest its own components to recover amino acids. This buys time, but it also consumes the mitochondria that produce the cell's energy.

Mitochondrial failureIn laboratory studies on prostate and gastric cancer cells, prolonged deprivation collapsed the mitochondrial membrane potential and flooded the cell with reactive oxygen species.

DNA damage and deathOxidative stress damages DNA. Nuclear DNA leaks into the cytoplasm, chromatin is digested, and the cell dies through a mix of apoptosis and an atypical, autophagy-driven death.

The cell's healthy neighbours experience none of this. They make their own arginine, their mTORC1 stays on, and they continue their normal work.

Why six months and not six weeks

A person can fast for three days without harm; after a week it becomes dangerous. Cancer cells are tougher. They enter a low-energy dormancy, recycle their own parts, and in some tumours even consume neighbouring cells. Weeks of deprivation are not enough. Months are.

Weeks 0 to 2 · Dormancy

Growth stops

Arginine gone within hours. mTORC1 off, AMPK on. Tumour cells stop dividing and conserve energy. Nothing visible yet on imaging.

Weeks 2 to 8 · Autophagy

Cells consume themselves

Self-digestion keeps cells alive at the cost of their own mitochondria. Oxidative stress rises. Tumour markers in the blood often begin to fall in this window.

Weeks 8 to 16 · Fragility

Open to combined therapy

Depleted cells have thinner reserves and leakier membranes. Low-dose chemotherapy, checkpoint inhibitors or radiation now hit harder than they would alone. First imaging review at week 8.

Weeks 16 to 24 · Exhaustion

Cell death and clearance

Reserves exhausted, DNA damaged, cells die. The immune system clears debris and surviving cells. Reviews at weeks 16 and 26 decide whether to stop, pause or extend.

The sequence is a model built from laboratory data and early clinical observation. Individual courses differ. Some patients show marker changes within weeks, others later or not at all.

Time is the therapy

Your immune system finds and destroys cancer cells every day of your life. It loses in advanced disease for one reason: the tumour makes new cells faster than the immune system can remove them.

Arginine deprivation attacks that ratio from both sides. Growth stops, so there are no new cells to clear. Starved cells become stressed and display more of the damage signals that natural killer cells and T cells recognise. Fasting-like states also raise NK and T-killer cell activity in the body. The immune system, no longer outpaced, gets the time to do what it was already trying to do.

This is why the programme is long, and why it is patient. The enzyme holds the tumour still. The killing is done by the body, and, where your oncologist chooses, by therapies combined with it.

What happens to healthy cells

Healthy cells carry a working urea cycle. When arginine disappears from the blood, they make it from citrulline, which the enzyme does not touch. Liver, kidney, muscle and immune cells all keep their supply.

Some functions are sensitive. Arginine is the raw material for nitric oxide, which widens blood vessels, and it plays a role in wound healing and in the activity of some immune cells. In trials of related enzymes these effects were mild and reversible: occasional changes in blood pressure, slower healing of existing wounds. They are monitored, not feared. Patients with a pre-existing urea-cycle disorder, who cannot make arginine themselves, are excluded for exactly this reason.

How a tumour can escape, and how we watch for it

A tumour under arginine pressure has one way out: switch ASS1 back on. Some do, through demethylation of the gene's promoter, often driven by the oncogene c-Myc. When that happens the tumour regains its own supply and the enzyme loses its grip.

Two things limit this. First, re-expressing ASS1 costs the tumour the growth advantage it gained by silencing it, so resistant tumours tend to grow more slowly. Second, resistance takes time to emerge, and the window before it does is exactly where combined therapies are most effective. Tumour markers, imaging at weeks 8, 16 and 24, and, where used, circulating tumour cell counts, show whether the tumour is still responding. If it is not, treatment stops.

Why combinations work better

A cancer cell with depleted energy, failing mitochondria and damaged DNA is a cell with fewer defences. Drugs that it would normally pump out, repair after, or outgrow now reach their target. Arginine deprivation is therefore not an alternative to standard treatment but a way to make it count for more.

Low-dose chemotherapyCisplatin, gemcitabine, docetaxel, pemetrexed, temozolomide. Studied in combination with ADI-PEG 20; the Phase III result in mesothelioma was achieved with chemotherapy added. Lower doses mean fewer side effects.

ImmunotherapyCheckpoint inhibitors (anti-PD-1, anti-PD-L1). Starved cells display more stress signals, and the immune system is the intended final actor of the therapy.

Targeted therapyTrastuzumab in HER2-positive breast cancer, venetoclax in leukaemia, azacitidine in myeloid disease.

RadiotherapyArginine-deprived cells repair radiation damage less well. Planned in glioblastoma together with temozolomide.

All combinations are decided by your treating oncologist, who stays in charge of your standard therapy throughout.

Terms

ArginineAn amino acid, a building block of proteins. Made by healthy cells in the urea cycle.

ArginaseAn enzyme that splits arginine into ornithine and urea. NGA-8000 is an arginase.

ASS1 and OTCTwo enzymes of the urea cycle. Tumours that have switched either off cannot make arginine.

AuxotrophyDependence on an external supply of a nutrient that the cell can no longer make.

AutophagyThe cell's recycling programme: digesting its own damaged or surplus parts.

mTORC1 and AMPKTwo switches that sense nutrients and energy. mTORC1 drives growth; AMPK drives conservation.

CEA, CA 15-3Tumour markers measured in blood. They track activity in many carcinomas and breast cancer respectively.

CTCCirculating tumour cells: cancer cells detached from the tumour and travelling in blood. Counting them helps track response.

Individual treatmentA physician's decision to use an unlicensed therapy for one named patient after full disclosure and consent. Not a trial, not a licensed product.

How arginine deprivation starves a tumour